Disrupting B and T cell Collaboration in Autoimmune Disease: T cell engagers versus CAR T cell therapy?

Kavina Shah,Maria Leandro,Mark Cragg,Florian Kollert,Franz Schuler,Christian Klein,Venkat Reddy

DOI: https://doi.org/10.1093/cei/uxae031

2024-04-20

Abstract:Summary B and T cells collaborate to drive autoimmune disease (AID). Historically, B and T cell (B-T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and organ transplantation benefit from targeted BCD with anti-CD20 monoclonal antibodies such as rituximab, ocrelizumab or ofatumumab. Refractory AID is a significant problem for patients with incomplete BCD with a greater frequency of IgD-CD27+ switched memory B cells, CD19+CD20- B cells and plasma cells that are not directly targeted by anti-CD20 antibodies, whereas most lymphoid tissue plasma cells express CD19. Furthermore, B-T cell collaboration is predominant in lymphoid tissues and at sites of inflammation such as the joint and kidney, where BCD may be inefficient, due to limited access to key effector cells. In the treatment of cancer, chimeric antigen receptor (CAR) T cell therapy and T cell engagers (TCE) that recruit T cells to induce B cell cytotoxicity have delivered promising results for anti-CD19 CAR T cell therapies, the CD19 TCE blinatumomab and CD20 TCE such as mosunetuzumab, glofitamab or epcoritamab. Limited evidence suggests that anti-CD19 CAR T cell therapy may be effective in managing refractory AID whereas we await evaluation of TCE for use in non-oncological indications. Therefore, here, we discuss the potential mechanistic advantages of novel therapies that rely on T cells as effector cells to disrupt B-T cell collaboration toward overcoming rituximab-resistant AID.

immunology

What problem does this paper attempt to address?

### Problems Addressed by the Paper

This paper primarily explores how novel therapies can disrupt the collaboration between B cells and T cells in autoimmune diseases (AID). Specifically:

1. **Background Issues**:
- The collaboration between B cells and T cells (B–T cell collaboration) leads to chronic inflammation in various autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
- Despite the availability of several B cell-targeted therapies (e.g., rituximab), some patients still do not respond well to these treatments.

2. **Limitations of Existing Therapies**:
- The widely used rituximab (a monoclonal antibody targeting CD20) cannot completely eliminate B cells in some cases, especially memory B cells (IgD−CD27+) and plasma cells (CD19+CD20−).
- These residual B cells and plasma cells continue to produce autoantibodies, leading to disease persistence or relapse.

3. **Research Objectives**:
- To explore novel therapies, particularly T cell-involved therapies (such as chimeric antigen receptor T cell therapy (CAR T cell therapy) and T cell engagers (TCE)), to overcome rituximab-resistant autoimmune diseases.
- To evaluate the potential mechanistic advantages of these novel therapies in disrupting B–T cell collaboration and to explore their feasibility in clinical applications.

In summary, this paper aims to provide new treatment options for autoimmune disease patients who do not respond well to existing therapies by disrupting the collaboration between B cells and T cells through novel therapies.